


PD 135158

Cat. No.:	HY-129810
CAS No.:	130325-35-8
Molecular Formula:	C ₄₂ H ₆₁ N ₅ O ₁₁
Molecular Weight:	811.96
Target:	Cholecystokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PD 135158 (CAM 1028) is a selective CCK _B receptor antagonist with an IC ₅₀ of 2.8 nM against mouse cortex CCK _B . PD 135158 shows anxiolytic activity ^[1] .									
IC₅₀ & Target	CCKBR 2.8 nM (IC ₅₀)	CCKAR 1232 nM (IC ₅₀)								
In Vivo	<p>PD 135158 (CAM 1028; 0.001-0.1 mg/kg; s.c.; once) enhances latent inhibition in the rat and shows antipsychotic potential^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Sprague-Dawley rats, conditioned suppression of drinking procedure model^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.001, 0.01, and 0.1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>0.2 mL/kg SC 30 min before preexposure and conditioning</td> </tr> <tr> <td>Result:</td> <td>Elicited a clear latent inhibition effect under conditions that did not lead to latent inhibition in control rats.</td> </tr> </table>		Animal Model:	Male Sprague-Dawley rats, conditioned suppression of drinking procedure model ^[2]	Dosage:	0.001, 0.01, and 0.1 mg/kg	Administration:	0.2 mL/kg SC 30 min before preexposure and conditioning	Result:	Elicited a clear latent inhibition effect under conditions that did not lead to latent inhibition in control rats.
Animal Model:	Male Sprague-Dawley rats, conditioned suppression of drinking procedure model ^[2]									
Dosage:	0.001, 0.01, and 0.1 mg/kg									
Administration:	0.2 mL/kg SC 30 min before preexposure and conditioning									
Result:	Elicited a clear latent inhibition effect under conditions that did not lead to latent inhibition in control rats.									

REFERENCES

[1]. Hughes J, et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728-32.

[2]. Gracey DJ, et al. PD-135,158, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat. Pharmacol Biochem Behav. 2000 Mar;65(3):459-63.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA